Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 177

1.

Ziprasidone augmentation for anxious depression.

Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI.

Int Clin Psychopharmacol. 2016 Jun 15. [Epub ahead of print]

PMID:
27306192
2.

Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder.

Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Heo JY, Kim KW, Kim ST, Kim DJ, Kim DK, Seo SW, Seong JK, Jeon HJ.

Transl Psychiatry. 2016 Jun 7;6(6):e835. doi: 10.1038/tp.2016.110.

3.

Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.

Papakostas GI, Martinson MA, Fava M, Iovieno N.

J Clin Psychiatry. 2016 May;77(5):e619-24. doi: 10.4088/JCP.14r09767.

PMID:
27249092
4.

Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder.

Baek JH, Kim HJ, Fava M, Mischoulon D, Papakostas GI, Nierenberg A, Heo JY, Jeon HJ.

Psychiatry Investig. 2016 May;13(3):321-6. doi: 10.4306/pi.2016.13.3.321. Epub 2016 May 18.

5.

Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.

Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH.

Am J Psychiatry. 2016 Jun 1;173(6):575-87. doi: 10.1176/appi.ajp.2016.15091228. Epub 2016 Apr 26.

PMID:
27113121
6.
7.

Identifying patients with depression who require a change in treatment and implementing that change.

Papakostas GI.

J Clin Psychiatry. 2016 Feb;77 Suppl 1:16-21. doi: 10.4088/JCP.14077su1c.03.

8.

Relationship between placebo response rate and clinical trial outcome in bipolar depression.

Iovieno N, Nierenberg AA, Parkin SR, Hyung Kim DJ, Walker RS, Fava M, Papakostas GI.

J Psychiatr Res. 2016 Mar;74:38-44. doi: 10.1016/j.jpsychires.2015.12.016. Epub 2015 Dec 20.

PMID:
26736040
9.

Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.

Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI.

J Clin Psychiatry. 2015 Dec;76(12):1635-41. doi: 10.4088/JCP.14m09587.

PMID:
26613389
10.

The pro-inflammatory profile of depressed patients is (partly) related to obesity.

Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI.

J Psychiatr Res. 2015 Nov;70:91-7. doi: 10.1016/j.jpsychires.2015.09.001. Epub 2015 Sep 3.

PMID:
26424427
11.

Antidepressants and their effect on cognition in major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2015 Aug;76(8):e1046. doi: 10.4088/JCP.13086tx5c. Review.

12.

Reply to commentary by Rothschild: "A Blood Test for Depression?".

Papakostas GI, Shelton RC, Henry ME, Bilello JA.

J Clin Psychiatry. 2015 Aug;76(8):e1038. doi: 10.4088/JCP.15lr10018. No abstract available.

13.

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.

Papakostas GI, Ionescu DF.

Mol Psychiatry. 2015 Oct;20(10):1142-50. doi: 10.1038/mp.2015.92. Epub 2015 Jul 7.

PMID:
26148812
14.

Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.

Yoo I, Woo JM, Lee SH, Fava M, Mischoulon D, Papakostas GI, Kim EJ, Chung S, Ha JH, Jeon HJ.

J Affect Disord. 2015 Oct 1;185:24-30. doi: 10.1016/j.jad.2015.06.038. Epub 2015 Jun 25.

PMID:
26142691
15.

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.

Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC.

Am J Psychiatry. 2015 Dec;172(12):1251-8. doi: 10.1176/appi.ajp.2015.14101251. Epub 2015 Jun 18.

16.

Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial.

Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D.

Pharmacopsychiatry. 2015 Jul;48(4-5):141-4. doi: 10.1055/s-0035-1549928. Epub 2015 May 26.

PMID:
26011569
17.

Understanding and managing Cognition in the Depressed Patient.

Papakostas GI, Culpepper L.

J Clin Psychiatry. 2015 Apr;76(4):418-25. doi: 10.4088/JCP.13086ah1c. Review.

18.

MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder.

Bilello JA, Thurmond LM, Smith KM, Pi B, Rubin R, Wright SM, Taub F, Henry ME, Shelton RC, Papakostas GI.

J Clin Psychiatry. 2015 Feb;76(2):e199-206. doi: 10.4088/JCP.14m09029.

19.

The nature of placebo response in clinical studies of major depressive disorder.

Papakostas GI, Ƙstergaard SD, Iovieno N.

J Clin Psychiatry. 2015 Apr;76(4):456-66. doi: 10.4088/JCP.14r09297.

PMID:
25700292
20.

Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.

Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI.

J Psychiatr Res. 2015 Mar;62:56-61. doi: 10.1016/j.jpsychires.2015.01.007. Epub 2015 Jan 26.

PMID:
25659187
Items per page

Supplemental Content

Loading ...
Write to the Help Desk